PubMed Health⌕ Search

Biomedical subjects

L Ambrozi

Publications and source records attributed to L Ambrozi.

At least 19 recordsLinked to original sources
PubMed1988

Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study.

Memantine was investigated in a phase II double-blind trial on 30 elderly patients by comparison with a placebo with the aid of several psychometric tests. It was found that vigilance, short-term memory, and concentration improve significantly under Memantine. It was also found that Memantine exerted a beneficial effect on psychiatric and neurological symptoms despite the presence of an organic psychosyndrome of many years' duration and multiple morbidity. The tolerance of the preparation was good in virtually all cases and a gradually increasing dosage is recommended. On the basis of these findings the authors assume that the therapeutic efficiency can be confirmed in a phase III trial.

Aged↗
PubMed1977

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

In a clinical trial the effect of L-deprenil, a selective irreversible inhibitor of monoamine oxidase (M.A.O.) "type B" in potentiating the anti-kinetic properties of levodopa has been investigated in 223 patients. Both drugs were given orally, levodopa as 'Madopar' (levodopa plus the peripherally acting decarboxylase inhibitor, benserazide) 250 mg three times daily and L-deprenil 5 mg once or twice daily. The addition of L-deprenil to madopar therapy resulted in a statistically significant (P less than 0-01-0-001) reduction in patients' functional disability on average within 60 min after a single oral dose and lasting for 1 to 3 days. Dyskinesia occurred in 16 patients, psychosis in 14, orthostatic hypotension in 5, and nausea in 8. Reduction of the L-deprenil dose to 5 mg in these patients eliminated some of the side-effects. Two-thirds of the patients with side-effects had suffered from parkinsonism for between 7 and 15 years. 14% of the patients failed to respond to madopar-deprenil therapy. It is suggested that L-deprenil may act through inhibition of brain M.A.O. as well as by a psychostimulant effect similar to that of amphetamine which occurs through the release of dopamine. Both mechanisms would make more dopamine available at dopamine receptor sites.

Administration, Oral↗
PubMed1977

Objectivation of latent psychoses.

A method--the flicker-frequency-analysis (FFA)--is reported by which it is possible to differentiate latent psychoses with neurotic sensation- and behaviour-disorders and "neuroses". The consecutive early treatment prevents irreversible lesions.

Adult↗